Scarica l'app Stockscreener
95.31
2.38%
-2.32
Dopo l'orario di chiusura:
96.82
1.51
+1.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies - AD HOC NEWS
FDA Approves Once-Daily Jakafi XR for Blood Disorders - MyChesCo
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Associa - PharmiWeb.com
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress - BioSpace
Incyte to Present Pipeline Strategy at May Investor Conferences - MyChesCo
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24 - Insider Monkey
Incyte Appoints Suketu Upadhyay as Chief Financial Officer - MyChesCo
Incyte Reports Q1 Revenue Growth as Pipeline Advances - MyChesCo
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations - Yahoo Finance
Incyte Corp. Receives Favorable Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)? - Yahoo Finance
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis - BioSpace
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
Incyte presents 24-week data for ruxolitinib cream in atopic dermatitis - Investing.com
Incyte eczema cream held disease control through 24 weeks - Stock Titan
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 - BioSpace
Incyte (NASDAQ: INCY) grants CFO RSUs, options and performance shares - Stock Titan
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Here's Why Incyte (INCY) is a Strong Growth Stock - Yahoo Finance
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
Incyte Corp. Receives Positive Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
Incyte (INCY) Receives FDA Orphan Designation for Pancreatic Can - GuruFocus
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $135 - Moomoo
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] - Quantisnow
Australia approves new therapy for transplant patients with chronic GVHD - Stock Titan
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings - Insider Monkey
Sanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extende - The National Law Review
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte (INCY) Gains FDA Approval for Jakafi XR Treatment - GuruFocus
FDA approves Incyte’s once-daily Jakafi XR formulation - Investing.com
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - Quantisnow
Incyte: Strong Business, But Risks Remain (NASDAQ:INCY) - Seeking Alpha
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
INCY SWOT Analysis: Strong Financial Performance Revealed in 10-Q Filing - GuruFocus
Vanguard Capital Management (INCY) discloses 6.32% ownership in Incyte Corp - Stock Titan
GC Wealth Management RIA LLC Takes Position in Incyte Corporation $INCY - MarketBeat
Vanguard Group Inc. Sells 40,189 Shares of Incyte Corporation $INCY - MarketBeat
INCY Maintained by Oppenheimer -- Price Target Raised to $90 - GuruFocus
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):